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Introduction: Although factors such as age, sex, diabetes, obesity and changes in cer-
tain laboratory investigations are important prognostic factors in COVID- 19 infec-
tion, these may not apply to all ethnic/racial groups. We hypothesized differences in 
routine biochemistry and haematology indices in Caucasian and a combined group of 
Black, Asian and Minority Ethnic (BAME) patients who tested positive for COVID- 19 
who died, compared to survivors.
Methods: We tested our hypothesis in 445 patients (229 Caucasian, 216 BAME) ad-
mitted to secondary care with proven COVID- 19 infection, in whom standard routine 
laboratory indices were collected on admission.
Results: After 28 weeks, 190 (42.7%) had died within 28 days of COVID diagnosis 
(97 Caucasians [42.4%], 93 BAMEs [43.1%], P = .923). A general linear model analysis 
found the ethnicity interaction with mortality to be significant for fibrinogen, ferritin 
and HbA1c (after controlling for age). In a multivariate analysis, a neutrophil/lympho-
cyte ratio > 7.4 and a urea/albumin ratio > 0.28 increased the odds of death for both 
the Caucasian and the BAME group. Additional factors increasing the odds ratio in 
the BAME group included age >60 years and being diabetic.
Conclusion: Neutrophil/lymphocyte ratio and urea/albumin ratio are simple metrics 
that predict death to aid clinicians in determining the prognosis of COVID- 19 and 
help provide early intensive intervention to reduce mortality. In the BAME groups, 
intensive monitoring even at younger age and those with diabetes may also help re-
duce COVID- 19 associated mortality.
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1  | INTRODUC TION
The severe acute respiratory syndrome coronavirus 2 (SARS- COV- 2) 
is an ribonucleic acid (RNA) virus that spreads rapidly via droplets, 
aerosols and contaminated surfaces.1 Clinical Coronavirus disease 
2019 (COVID- 19) presentation ranges from asymptomatic, through 
to mild influenza- like symptoms to multiple organ failure and 
death.2- 4 The reported mortality worldwide ranges from 8.1% to 
33% in hospitalized patients.2,5,6 Gender, age, comorbidities includ-
ing diabetes, hypertension and obesity, changes in laboratory inves-
tigations including haematological and biochemical characteristics 
in patients with COVID- 19 are emerging as important prognostic 
factors.2,7 Many of these laboratory indices, including a decreased 
platelet count and increased prothrombin time, ferritin, lactate de-
hydrogenase, D- dimer and neutrophil/lymphocyte ratio, have also 
been linked to high mortality in a South Asian population.8
In the United Kingdom (UK), cases within patients from Black 
(African and Afro- Caribbean), Asian and Minority Ethnic (BAME) 
groups have a worse prognosis than that seen in Caucasians.9- 11 
Perkin et al12 reported deaths in patients from the BAME commu-
nities in the COVID- 19 group during the pandemic period to be 
significantly increased (P = .02). The increase was reported to be 
independent of comorbidities, sex, age or socioeconomic depriva-
tion. Major risk factors for mortality were male sex, diabetes melli-
tus, multiple comorbidities and being from the BAME communities. 
Bannaga et al11 found BAME patients were more likely to require 
intensive care unit (ICU) admission (P = .008).
Many hospitals across the world have been collecting data pro-
spectively as patients with COVID- 19 first presented, looking for 
patterns in clinical findings and routine laboratory markers that 
may predict risk of a poor health outcome in a variety of patient 
groups. Collected during an emerging pandemic, many of these se-
ries have limitations, but in addition to learning from their individual 
outcomes, publication offers the possibility of future data pooling 
and meta- analysis to increase the reliability of the findings. Early 
in the pandemic, the importance of coagulation and inflammatory 
markers was noted.13 Bannaga et al11 noted increased mortality 
from COVID- 19 was associated with age >65 years (P = .026), heart 
disease (P = .009) and elevated C- reactive protein (CRP) (P = .011), 
raised neutrophils (P = .047) and altered neutrophil/lymphocyte 
ratio (P = .028). Taj et al14 concluded that leucocytosis, neutrophilia, 
lymphopenia, elevated neutrophil/lymphocyte ratio, activated par-
tial thromboplastin time (APTT), fibrinogen and fibrin degradation 
product (D- dimer), lactate dehydrogenase (LDH), serum ferritin and 
CRP are associated with severity of COVID- 19 disease.
As 50% of the population in our catchment area are from eth-
nic minorities,15 the region has been seeking to identify the reasons 
for the difference in outcomes in BAME patients. We hypothesized 
that certain routine haematology and biochemistry indices may be 
altered in those Caucasians and BAME patients who subsequently 
died within 28 days of a positive COVID- 19 test and that pattern 
identification would facilitate prediction of those at high risk of se-
vere disease and rapid deterioration.
2  | MATERIAL S AND METHODS
2.1 | Study design and participants
This retrospective cohort study included all admitted patients test-
ing positive for COVID- 19 from a single centre National Health Trust 
in the UK between 3rd February 2020 and the 4th September 2020. 
Data from 445 patients (>18 years) were included in the analysis, 
252 were males and 193 were females. Of the 255 patients that 
survived, 132 were Caucasian and 123 were from BAME group. Of 
these, coding showed that 23 were Black, 56 were Asian, 8 were 
mixed race and 36 were only coded as BAME without a subgroup 
code. Of the 190 patients that died, 97 were Caucasian, and 93 were 
from the BAME group (Black 32, Asian 41, mixed race 3, not coded 
17). Patients were classified as Caucasian or BAME, and as survi-
vors or fatalities. Furthermore, 10% (46 out of 445) of patients were 
admitted to intensive care unit (ICU) of which 70% (32 out of 46) 
patients were from BAME group. This study was granted ethical ap-
proval by the Integrated Research Approval System (IRAS) and spon-
sored by research and development committee of the Trust (IRAS 
number 289571). All patients were treated using the local trust and 
the NHS protocols irrespective of their ethnicity. All patient results 
were collected within 3 days of COVID- 19 diagnosis.
2.2 | Laboratory procedures
Patients were identified as COVID- 19 positive by reverse tran-
scriptase polymerase chain reaction (RT- PCR) from throat/nose 
swabs on a ROCHE COBAS™ analyser (Roche Ltd.). Nasopharyngeal 
or oropharyngeal samples were collected from patients for the 
detection of SARS- CoV- 2 RNA. The Xpert® Xpress SARS- CoV- 2 
(Cepheid Ltd.) real- time RT- PCR assay was performed to achieve 
qualitative detection of SARS- CoV- 2 RNA.
A Sysmex™- XN (Sysmex LTD.) automated haematology analy-
ser was used for routine full blood count analysis. Instrumentation 
Laboratory ACL350™ and ACL550™ analysers (Werfan Ltd.) were 
used to measure the prothrombin time, from which the internal 
normalized ratio (INR) was calculated, the partial prothrombin time 
(PTT) and the D- dimer level. An Abbot Architect™ analyser was used 
to determine quantitative biochemical analysis including urea and 
electrolytes, albumin, alkaline phosphatase (ALP), alanine amino-
transferase (ALT), creatinine, LDH, troponin, CRP and ferritin.
2.3 | Statistical analysis
Continuous variables were presented as either median (interquartile 
range) or mean/(±standard deviation) depending on distribution (dis-
tribution of normality was checked by D’Agostino Pearson's normal-
ity test). Continuous variables were analysed using a Kruskal- Wallis 
test with multiple comparisons among groups analysed using the 
Bonferroni adjustment method test or a one- way ANOVA analysis 
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with a post hoc Tukey's test where appropriate. Furthermore, a 
Mann- Whitney U test was used to determine any differences be-
tween the Black and Asian population within the BAME group. To 
determine interaction between ethnicity and morbidity on the de-
pendent variable, a general linear model was used adjusting for age. 
A two- sided test P < .05 was considered statistically significant. 
Sample size varied because of missing data as detailed in the tables. 
Data were subject to univariate analyses: those with a significance 
<0.05 were subsequently analysed by multivariate methods.
To explore the risk factors associated with mortality for 
Caucasian and BAME patients, multivariate logistic regression 
models were used. Considering the total number of deaths per 
group (97 and 93 within the Caucasian and BAME groups, re-
spectively) in this study and to avoid over fitting in the model, 
four variables were chosen for multivariable analysis for both the 
Caucasian and BAME group on the basis of a univariate analy-
sis. Variables were excluded from the univariate analysis if the 
number of events was too small to calculate the odds ratio and if 
the receiver operator characteristic (ROC) area under the curve 
was <0.6. For the ratios proposed, the ROC was used to evalu-
ate optimal thresholds for individual biomarkers. A multivariate 
logistic regression model was then fitted, to estimate the ef-
fect of indicators on inpatient mortality for critically ill patients. 
Based on the univariate analysis for the Caucasian group, dia-
betes, neutrophil/lymphocyte ratio, urea/albumin ratio and the 
(ALP × ALT)/albumin index showed the highest discriminatory 
power and were chosen as variables for our multivariate logistic 
regression model. Based on the univariate analysis for the BAME 
groups, age, diabetes, neutrophil/lymphocyte ratio and urea/al-
bumin ratio were selected as variables for our multivariate logistic 
regression model. A two- sided α < .05 was considered statistically 
significant. All statistical analyses were performed using SPSS™ 
software (version 26).
3  | RESULTS
Table 1 shows clinical and demographics of the subjects, limited to 
those were captured on admission. Survivors, in both groups, were 
younger than those who died. In the study sample, diabetes was not 
linked to Caucasian deaths but was strongly linked to BAME deaths. 
The majority of patients where body mass index (BMI) was possi-
ble to be calculated were overweight (151 out of 233 patients), and 
nearly half were diagnosed with diabetes (199 out of 445 patients). 
Hypertensive presentation and a raised heart rate (HR > 100) on ad-
mission were not prevalent; however, an increased respiratory rate 
(RR) was observed (>20 breaths per minutes, in 175 out of 411 pa-
tients). Further, a peripheral venous oxygen saturation (SpO2) < 94 
was prevalent in approximately 25% of all patients. Furthermore, 
of the Caucasian men, 44% died, of the Caucasian women, 40% 
died whereas of the BAME group men, 48% died, and of the BAME 
women, 37% died.
TA B L E  1   Demographic and clinical observations findings of patients on admission
P value Caucasian (C) P value BAME (B) P value
Overall Survivors (S) Fatalities (F) CS vs CF Survivors (S) Fatalities (F) BS vs BF
Age (y) <0.0001 78 [68- 87] 81 [73- 87.5] .98 56 [41.75- 73.25] 79 [67- 85] <.0001
N 132 97 123 93
Gender
Male .613 73 57 64 58
Female .661 59 40 59 35
Body mass index .103 25.5 [22.8- 31.2] 27.2 [23.4- 31.6] .107 28.3 [25.5- 33.9] 26.7 [23.2- 31.7] .999
n 75 48 72 38
Diabetes .151 46 (36%) 39 (40%) .84 49 (42%) 65 (68%) <.001
n 127 97 118 93
Hypertension 
>140/90 in mm Hg
.208 19/116 (16%) 18/96 (19%) 20/107 (19%) 9/93 (10%)
n 116 96 107 91
Respiratory Rate 
(breaths/min)
.012 19.5 [18- 22] 20 [18- 24] .808 20 [18- 24] 23 [18- 27] .999
n 116 96 108 91
Heart rate 
(beats/min)
.832 83 [69- 99] 88 [77- 101] .182 90 [80- 101] 89 [79- 106] .999
n 116 96 108 91
SpO2 (%) .590 96 [94- 97] 96 [93- 97] .999 96 [94- 98] 96 [93- 98] .999
n 116 96 108 91
Note: Data are median (IQR), n (%), or n/N (%). P values were calculated by a Kruskal- Wallis test with a post hoc Dunn's multiple comparison test or 
Fisher's exact test, as appropriate.
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Table 2 shows haematology data. Differences in the haemoglobin 
(Hb) across men and women, the mean corpuscular volume (MCV), 
white blood cell count (WBC), neutrophil, lymphocyte, monocyte and 
eosinophil count, INR, D- dimer and HbA1c concentrations (P < .05, for 
all parameters) were observed across Caucasian and BAME between 
survivors and fatalities. The median MCV value was higher in fatalities 
compared with survivors. However, MCV values were significantly 
lower in BAME survivors and fatalities data than that seen in 
Caucasians (overall P ≤ .0001). This study demonstrated significantly 
higher WBC and neutrophil count as well as a lower lymphocyte count 
in the Caucasian fatality and survivors group, compared with BAME 
fatality and survivors groups (overall P = .004, P ≤ .001 and P ≤ .0001, 
TA B L E  2   Haematological findings of COVID- 19 positive patients on admission
P value Caucasian (C)
P 
value BAME (B) P value
Over all Survivors (S) Fatalities (F)
CS vs 




Male .023 132 (112- 151) 129 (102- 157) .999 130 (109- 152) 120 (98- 142) .066
<125 27/73 (40%) 23/56 (41%) 23/64 (36%) 33/58 (57%)
Female .044 123 (103- 143) 117 (92- 142) .607 118 (101- 135) 109 (83- 135) .248
<115 23/59 (40%) 18/40 (45%) 22/43 (51%) 20/32 (63%)
MCV (fL) <.0001 90.9 [88.1- 95.4] 94.3 [89.85- 98.35] .022 86.2 [81.2- 90.6] 89.2 [84.6- 94.23] .011
WBC × 109/L .004 8.5 [6.2- 11.3] 9.55 [6.5- 12.5] .991 7.3 [5.65- 9.45] 8.85 [6.96- 11.80] .019
>11 36/132 (27%) 35/96 (36%) 25/122 (20%) 26/90 (29%)
Neutrophil 
count × 109/L
<.0001 6.78 [4.41- 9.7] 7.92 [5.14- 10.71] .168 5.33 [3.85- 7.44] 7.17 [5.55- 10.38] .001
>7.5 49/132 (37%) 50/96 (52%) 30/122(25%) 41/90 (46%)
Lymphocyte 
count × 109/L
<.0001 0.95 [0.6- 1.35] 0.725 [0.53- 0.99] .021 1.15 [0.81- 1.53] 0.77 [0.55- 1.23] <.0001
<1 70/132 (53%) 46/132 (35%) 56/90 (62%)
Monocyte 
count × 109/L
.008 0.58 [0.37- 0.82] 0.58 [0.29- 0.82] .999 0.46 [0.31- 0.63] 0.46 [0.26- 0.69] .999
<0.2 6/132 (5%) 13/132 (10%) 17/90 (19%)
>0.8 33/132 (25%) 20/132 (15%) 12/ 90 (13%)
Eosinophil 
count × 109/L
.005 0.02 [0.005- 0.08] 0.01 [0.005- 0.03] .005 0.01 [0.005- 0.07] 0.005 [0.005- 0.053] .999
Platelet 
count × 109/L
.136 242 [187- 303] 218 [154- 280] .999 231 [182.5- 320] 227.5 [174.8- 295.5] .999
<150 13/132 (10%) 20/95 (21%) 16/132 (12%) 12/90 (13%)
INR .002 1.18 [1.1- 1.29] 1.275 [1.12- 1.48] .147 1.15 [1.07- 1.25] 1.19 [1.12- 1.35] .177
>1.2 42/95 (44%) 43/72 (60%) 31/89 (35%) 32/72 (44%)
PTT .072 1.01 [0.91- 1.07] 1.065 [0.99- 1.31] 0.89 [0.87- 1.03] 1.055 [0.9425- 1.495]
>1.2 4/10 (40%) 4/12 (33%)
D- dimer (FEU µg/ml) .004 1.07 [0.89- 15.25] 2.36 [1.05- 12.35] .999 1.63 [0.61- 1.96] 7.52 [2.13- 31.93] .003
>0.5 11/11 (100%) 12/13 (92%) 13/15 (87%) 24/25 (96%)
Fibrinogen (g/L) .118 2.2 [1.4- 3.0] 6.6 [4.1- 9.8] 7.2 [5.2- 8.9] 8.5 [5.25- 10]
>4 1/2 (50%) 8/11 (72%) 6/7 (86%) 18 (86%)
Ferritin (µg/L) .459 649.5 
[225.8- 1126]
647.5 [231.8- 1526] .999 556.5 [176- 1550] 686.0 [202.5- 2508] .999
>300 50/72 (69%) 34/50 (68%) 42/66 (64%) 35/49 (71%)
HbA1c (mmol/mol) <.0001 41 [38- 47] 42 [38- 49.5] .999 43.5 [40- 55.5] 51 [44- 67] .006
>42 46/112 (41%) 39/85 (46%) 49/88 (56%) 65/83 (78%)
Note: Non- normally and normally distributed continuous variables are presented as medians (interquartile ranges, IQR) and mean (standard 
deviation), respectively, as well as n/N (%). Continuous variables were analysed using a Kruskal- Wallis test with a post hoc Dunn's multiple 
comparison test or a one- way ANOVA with a post hoc Tukey's test where appropriate.
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respectively). Lymphopenia was significant in the fatality groups com-
pared to their respective survivors (P = .021 and P ≤ .0001 in the 
Caucasian and BAME group, respectively). Finally, the generalized lin-
ear model (GLM) analysis (Table S1) found the ethnicity factor (BAME 
group) to be significant for monocyte count (P = .007).
The median D- dimer and fibrinogen levels of all four groups 
were above the reference range (0.5 µg fibrinogen equivalent units 
(FEU)/mL and 4 g/L, respectively) of the available patient data 
(Table 2). The D- dimer levels were higher in those who died in both 
groups, but the relative increase was greater in the BAME group. 
Furthermore, the fibrinogen level was significantly higher in the 
Black fatality population compared with Asian fatalities (P < .03), 
(Table S2). The GLM analysis (Table S1) found the mortality and 
ethnicity factor interaction to be significant for fibrinogen with a 
possible significant effect of ethnicity on mortality (P = 024 and 
0.25, respectively). The median HbA1c level was significantly differ-
ent across the groups (P ≤ .0001), the BAME group having higher 
values (Table 2). The GLM analysis adjusted for age found the mor-
tality (P = .007) with ethnicity (P ≤ .0001) factor to be significant for 
HbA1c; thus, there was a significant effect of ethnicity on mortality 
(Table S1).
Table 3 shows biochemistry results. Differences in the urea, 
sodium, potassium, albumin, creatinine, ALT, CRP, LDH and tropo-
nin- I (P < .05) levels were observed across Caucasian and BAME 
survivors and fatalities. In the subgroup analysis, MCV, lympho-
cyte, eosinophil, urea, sodium, albumin, CRP, LDH and troponin- I 
were significantly different in Caucasian survivors compared to 
Caucasian fatalities. Similarly, MCV, WBC, neutrophil, lymphocyte, 
D- dimer, HbA1c, urea, sodium, potassium, albumin, creatinine, 
CRP and troponin- I were significantly different in BAME survi-
vors compared BAME fatalities. Serum urea (P ≤ .0001 for both 
Caucasian and BAME) and serum sodium (P = .027 and P ≤ .0001 
for Caucasian and BAME, respectively) concentrations were sig-
nificantly higher in the fatality groups, whereas serum albumin was 
TA B L E  3   Biochemical findings of COVID- 19 positive patients on admission
P value Caucasian (C) P value BAME (B) P value
Over 
all Survivors (S) Fatalities (F)
CS vs 
CF Survivors (S) Fatalities (F)
BS vs 
BF
Urea (mmol/L) <.0001 8.05 [5.325- 11.48] 11.15 [8.125- 19.2] <.0001 6.1 [4.5- 10.6] 13.6 [8.85- 21.48] <.0001
>7.8 65/129 (50%) 74/96 (77%) 42/121 (35%) 74/90 (82%)
Sodium (mmol/L) <.0001 137 [135- 141] 140 [137- 143.8] .027 136 [133- 139] 140 [134- 143.3] <.0001
<133 18/129 (14%) 8/96 (8%) 21/121 (17%) 12/90 (13%)
>146 16/129 (12%) 15/96 (16%) 4/121 (3%) 18/90 (20%)
Potassium (mmol/L) .003 4.01 (3.36- 4.66) 4.07 (3.36- 4.77) .999 4.14(3.56- 4.72) 4.45 (3.51- 5.38) .021
<3.5 27/122 (22%) 18/89 (20%) 11/109 (10%) 8/84 (10%)
Albumin (g/L) <.0001 35.61 
(30.40- 40.82)
32.30 (27.07- 37.53) .0002 36.45 
(30.61- 42.29)
31.99 (25.90- 38.1) <.0001
<5 49/115 (43%) 61/91 (67%) 37/104 (36%) 54/87 (62%)
Creatinine (µmol/L) <.0001 89.5 [72- 118.8] 104.5 [75- 162] .068 94 [72- 124] 132 [88.75- 239] <.0001
>133 24/124 (19%) 35/96 (36%) 25/115 (22%) 44/90 (49%)
ALP (U/L) .195 89 [74- 118] 93 [74- 139] .999 83.5 [65- 115.8] 87 [62.5- 116.5] .999
>130 23/115 (20%) 25/91 (27%) 22/104 (21%) 19/85 (22%)
ALT (U/L) .002 25 [17- 38] 26 [17- 52] .676 32 [21- 57] 34 [18.5- 58] .999
>41 21/113 (19%) 30/91 (33%) 55/103 (53%) 34/85 (40%)
Bilirubin (µmol) .061 11 [8- 17] 12 [8- 18] .999 10 [7- 17] 11 [7- 16] .999
>21 17/114 (15%) 9/90 (10%) 5/104 (5%) 9/83 (11%)
CRP (mg/L) <.0001 98 [31- 168] 130 [70.75- 235.5] .012 83 [40- 174] 157 [102- 246] <.0001
>1 107/111 (96%) 92/92 (100%) 102/103 (99%) 85/86 (99%)





>5 65/65 (100%) 43/45 (96%) 56/56 (100%) 40/42 (95%)
Troponin- I (ng/L) <.0001 26.5 [13- 69.75] 71 [24.5- 201.5] .052 11 [4- 31] 63 [29.5- 212] <.0001
>3 60/60 (100%) 59/61 (97%) 51/67 (76%) 61/61 (100%)
Note: Non- normally and normally distributed continuous variables are presented as medians (interquartile ranges, IQR) and mean (standard 
deviation), respectively, as well as n/N (%). Continuous variables were analysed using a Kruskal- Wallis test with a post hoc Dunn's multiple 
comparison test or a one- way ANOVA with a post hoc Tukey's test where appropriate. For variables with overall P > .05, we did not perform group 
comparisons.
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significantly lower in both fatality groups when compared with 
each survivor group (P = .0002 and P ≤ .0001 for Caucasian and 
BAME groups, respectively). The potassium and creatinine levels in 
the BAME fatality group were significantly higher compared with 
both Caucasian groups (P = .003 and P ≤ .0001, respectively). The 
urea to albumin ratio was significantly different across the groups 
at P ≤ .0001 (Table 3). The GLM analysis (Table S1), adjusted for age, 
observed the mortality and ethnicity interaction was significant 
for this ratio (mortality P = .005 and ethnicity P ≤ .0001). Of the 
liver function tests, the ALT concentration in the Caucasian group 
was significantly lower compared with BAME group (P = .002). The 
(ALP × ALT)/albumin index was significantly different across the 
groups (P ≤ .0001).
The median CRP, ferritin and LDH concentration of both 
Caucasian and BAME groups remained above the reference range 
(Tables 2 and 3). The troponin- I level in both fatality groups was 
significantly higher compared with both survivor groups. Further, 
the LDH concentration in the Caucasian survivor group was signifi-
cantly lower compared with both fatality groups. Both the mortal-
ity (P = .023) and ethnicity (P = .043) interaction was significant for 
ferritin; thus, there was a significant interaction/effect of ethnicity 
on mortality (Table S1). Further subgroup analysis into the BAME 
group revealed both the LDH (P = .006) and troponin- l (P = .04) were 
significantly higher in Black fatality population (LDH 682 [521- 846] 
and troponin- I 140 [60- 353]) compared with Asian fatalities (LDH 
[406/253- 626] and troponin [46/22- 166] (Table S2).
The neutrophil- to- lymphocyte ratios were significantly higher 
in both fatality groups compared to their respective survivors 
(P ≤ .0001, Caucasians at P = .006 and BAME at P ≤ .0001) (Table 4).
In the univariate logistic regression analysis for the Caucasian 
group, a raised creatinine, CRP, neutrophil/lymphocyte, urea/albu-
min and (ALP × ALT)/albumin index, as well as increasing respiratory 
rate, were all associated with death. The optimal threshold for all 
indices as well as the CRP, ferritin and LDH was determined using 
the ROC area under the curve.
In the multivariable logistic regression model, we included 
201 patients with complete data for all variables (Figure 1). 
Neutrophil/lymphocyte ratio, and higher urea/albumin ratio and 
higher (ALP × ALT)/albumin values above 7.4, 0.28 and 238, respec-
tively, increased the odds of death. In the univariable logistic re-
gression analysis for the BAME group, the odds of in- hospital death 
were higher in those >60 years and diabetics. Increasing HbA1c 
raised MCV, creatinine, CRP as well as neutrophil/lymphocyte, 
urea/albumin and (ALP × ALT)/albumin indices above those set by 
the ROC analysis also increased the risk. We included 185 patients 
with complete data for all variables in the multivariable logistic re-
gression model (Figure 1). Being older than 60 years of age, diabetic 
as well as a neutrophil/lymphocyte and urea/albumin ratio above 7.4 
and 0.28, respectively, increased odds of death.
4  | DISCUSSION
This study aimed to analyse differences in blood parameters be-
tween the Caucasian and BAME groups of COVID- 19 patients and 
to further understand risk factors for mortality from a single centre 
in the West Midlands, UK, with a multi- ethnic population observing 
a disproportionally higher death rate.8 The study identified several 
risk factors including new laboratory indices for mortality in both 
Caucasian and BAME groups. A raised neutrophil/lymphocyte ratio 
and/or raised urea/albumin ratio were found to be accurate and 
practical indicators for risk of COVID- 19 associated mortality in 
both Caucasian and BAME groups. Additionally, among the clinical 
and demographic parameters in this study, we found age >60 years 
and diabetes mellitus directly predicted mortality in the BAME 
group. Further, a raised (ALP × ALT)/albumin ratio was a predictor of 
COVID- 19 associated mortality in Caucasians only.
Patients with severe COVID- 19 have previously been observed 
to have a high leucocyte count, low lymphocyte counts and high 
neutrophil/lymphocyte ratio, as well as lower percentages of 
monocytes, eosinophils and basophils.2,5,9,10,16,17 Lymphopenia and 
increased neutrophil- to- lymphocyte ratio (NLR) (>7.8) in our study 
was found to be associated with increased mortality, indicating 
a serious pathological and biochemical disturbance and poten-
tial critical condition in severely infected cases16 which may be a 
result of excessive inflammation and immune suppression in sep-
sis triggered by SARS- CoV- 2 infection. NLR did not, however, dis-
criminate BAME from Caucasian group perhaps as BAME groups 
have a lower basal neutrophil count (ethnic neutropenia due to the 
Duffy gene polymorphism18), whereas lymphopenia was worse in 
the BAME groups suggesting their severity of infection was high. 
In sepsis, neutrophils are hyper- activated with delayed apoptosis 
disorder19 a common event in severe COVID- 19.20 Recent stud-
ies have shown neutrophilia and neutrophil activation signature 
is present on first day of hospitalization with SARS- CoV- 2 infec-
tion who later on require transfer to intensive care unit. Strongest 
TA B L E  4   Ratios are presented as medians (IQR)
P value Caucasian (C) P value BAME (B) P value
Overall Survivors (S) Fatalities (F) CS vs CF Survivors (S) Fatalities (F) BS vs BF
Neutrophil/
lymphocyte
<.0001 7.0 (3.7- 13) 10.4 (6.3- 16) .006 4.5 (3.2- 8.1) 9.4 (5.6- 17) <.0001
Urea/Albumin <.0001 0.22 (0.16- 0.35) 0.34 (0.29- 0.61) <.0001 0.17 (0.11- 0.27) 0.40 (0.28- 0.68) <.0001
(ALP × ALT)/albumin <.0001 66 (36- 125) 46 (71- 177) <.0001 80 (44- 186) 87 (47- 197) <.0001
Note: Continuous variables were analysed using a Kruskal- Wallis test with a post hoc Dunn's multiple comparison test.
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predictors of critical illness were high resistin, lipocalin- 2, hepato-
cyte growth factor, interleukin- 8 and granulocyte colony stimu-
lating factor.21 Numerous factors may contribute to COVID- 19 
associated lymphopenia. Lymphocytes express the angiotensin 
converting enzyme- 2 (ACE2) receptor on their surface22; thus, 
SARS- CoV- 2 may directly infect those cells and ultimately lead 
to their destruction. Whether people within the BAME grouping 
express excessive ACE2 receptors on their lymphocytes remains 
a postulation. Furthermore, T- cell apoptosis,23 as well as the cy-
tokine storm, and tumour necrosis factor (TNF)- alpha, may also 
promote lymphocyte apoptosis.4 Lymphopenia was worse in the 
BAME groups suggesting their severity of infection was high.
Our results are consistent with those of Bannaga et al,11 who 
showed lower serum albumin in nonsurvivors admitted with 
COVID- 19. Hypoalbuminaemia may occur as a result of acute inflam-
matory response and hepatic injury. The raised serum urea concen-
trations observed could either suggest underlying chronic kidney 
disease, potentially linked to diabetes, hypertension or acute illness, 
with dehydration leading to reduced renal perfusion. This was sup-
ported by the demonstration of hypernatremia in this study. Hence, 
attention should be paid in maintaining kidney perfusion and hydra-
tion to reduce mortality, particularly in those with chronic kidney 
disease. Particular attention should be paid to patients admitted 
to intensive care units, where inotrope support may reduce renal 
F I G U R E  1   Risk factors associated with in- hospital death. Univariate risk factors associated with mortality for the Caucasian (plot A) 
and (plot B) BAME patient groups followed by a multivariate analysis for the Caucasian (plot C) and (plot D) BAME patient groups for 201 
and 185 patients with complete data for all variables, respectively. Neutrophil/lymphocyte, urea/albumin, LDH/albumin, CRP/albumin, 
ferritin/albumin, (ferritin × CRP)/albumin, (Alk 2 × ALT AT)/albumin indices were converted to binary variables according to the optimal 
cut- off value by employing receiver operating characteristic (ROC) analysis. OR, odds ratio and statistical significance shown with asterisks 
where *P ≤ .05, **P ≤ .01, ***P ≤ .001 and ****P ≤ .0001
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perfusion. The renal dysfunction could also be due to vasculopathy 
often seen in COVID- 19 patients.25
Although we did not observe significant elevations in bilirubin 
or aspartate aminotransferase (ALT) levels, the multivariate logistic 
regression analysis observed the (ALP × ALT)/albumin index (>238) 
was associated with increased odds of death in the Caucasian fatal-
ity group. This is likely to be due to hypoalbuminaemia due to tissue 
leak consequent upon inflammation and perhaps reduced hepatic 
synthesis.
Older age has been reported as an important independent pre-
dictor of mortality.7,10 We found age >60 years increased the odds of 
death within the BAME group. The age- dependent defects in T- cell 
and B- cell function as well as the excess production of type 2 cyto-
kines could lead to a deficiency in control of viral replication and a 
more prolonged pro- inflammatory responses resulting in a poor out-
come.26 It is, however, not clear why only the BAME population have 
higher mortality at younger age. Data collected in UK have shown 
that the BAME population was 1.7- 3.5 times more likely to die from 
COVID- 19 at any age as compared to Caucasian populations sug-
gesting an either an inherent risk or due to other comorbidities and 
socioeconomic factors.27
Patients diagnosed with diabetes have been reported to have 
a higher risk of mortality with COVID- 19 infection28- 30. A third of 
COVID- 19- related deaths in hospital in England between 1 March 
1 and 11 May 2020 were in people with diabetes.31 We found dia-
betes to increase the odds of death in BAME group which may be 
explained by the higher HbA1c levels in the BAME group. Diabetes 
is a chronic, low- grade inflammatory disease often presenting a 
dysregulated immune response. Furthermore, viral infection may 
cause fluctuations in blood glucose in diabetic patients thus ad-
versely affecting recovery.31 The higher HbA1c concentrations 
in the BAME group indicate a poor diabetic management of our 
study population implying poor health care and education of this 
ethnic group.
Our study has limitations. First, due to the retrospective study 
design, not all laboratory tests were carried out or recorded in all 
patients, particularly INR, PTT, D- dimer, fibrinogen, ferritin, LDH 
and troponin. Therefore, their role might be underestimated in pre-
dicting in- hospital death. D- dimer is particularly important as higher 
levels have been correlated with death.32 Secondly, lack of informa-
tion regarding drug treatment like corticosteroids and immunomod-
ulatory agents might have also influenced the clinical outcomes in 
some patients. Furthermore, data regarding comorbidities were not 
intended to be collected in this study; however, data from hospital 
statistics show that overall 56% of patients had diabetes, 37% had 
hypertension, 24% had chronic kidney disease and 16% had cancer 
which could have affected clinical outcomes. Third, interpretation 
of our findings might be limited by the sample size. However, by 
including all adult patients across the trust, we believe our study 
population is representative of cases diagnosed and treated in West 
Birmingham.
To the best of our knowledge, this is one of the few retrospec-
tive studies among patients with COVID- 19 that have compared 
between the laboratory abnormalities across different ethnic 
groups. We believe it will be useful for clinicians to use neutro-
phil/lymphocyte ratio above 7.4 and urea/albumin ratio above 
0.28, (ALP × ALT)/albumin index above 238 being (specific to 
the Caucasian group ) as indicators of severity and consider ap-
propriate intervention to reduce mortality in COVID- 19. Recent 
evidence of neutrophil activation markers predicting severity of 
critical illness could confer therapeutic intervention. Furthermore, 
the BAME subgroup of relatively younger age (>60 years) and 
those with diabetes are at higher risk of death. They should be 
shielded or appropriately protected and also intensely monitored 
should they present with COVID- 19 infection. Attention must be 
given to good health education about diabetic control in all ethnic 
groups but more so in BAME groups. With the availability of so 
many COVID- 19 vaccines, these high- risk groups should be tar-
geted early for vaccination.
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